Underestimation of chronic renal dysfunction after liver transplantation: ICEBERG study

Table 1 Demographics and clinical characteristics of the 402 liver transplant recipients

Variables	n (%)
Age at transplant (yr), mean ± SD	52.4 ± 9.8
Gender (male)	288 (71.6)
Ethnicity (Caucasian)	400 (99.5)
Donor age, mean ± SD	47.0 ± 18.9
Time since transplantation (yr), mean ± SD	6.9 ± 3.9
Pre-transplant comorbidities
Diabetes mellitus	71 (17.7)
Hypertension	36 (9.0)
Dyslipidemia	13 (3.2)
Coronary heart disease	8 (2.0)
Reason for transplantation
Alcoholic cirrhosis without hepatocellular carcinoma	132 (32.8)
Hepatocellular carcinoma (in HCV or HBV-related liver cirrhosis, alcoholic cirrhosis or non-cirrhotic liver)	92 (22.9)
HCV-related liver cirrhosis without hepatocellular carcinoma	74 (18.4)
Cholestatic liver disease	24 (6.0)
HBV-related liver cirrhosis without hepatocellular carcinoma	23 (5.7)
Acute liver failure	9 (2.2)
Others	45 (11.2)
Induction therapy	68 (16.9)
Immunosuppressive treatment (at discharge)
Monotherapy	34 (8.5)
Cyclosporine	14 (3.5)1
Tacrolimus	20 (5.0)1
Combined therapies	368 (91.5)
Cyclosporine-based	155 (38.6)1
Tacrolimus-based	149 (37.1)1
mTOR inhibitor-based	63 (15.7)1
Others	1 (0.3)1

¹Percentages with respect to the total population. HCV: Hepatitis C virus; HBV: Hepatitis B virus; mTOR: Mammalian target of rapamycin.